Enzon Pharmaceuticals tenders for 4.5% convertibles due 2009

By Jennifer Chiou

New York, June 6 - Enzon Pharmaceuticals, Inc. announced the start of a cash tender offer for up to $180 million of its 4.5% convertible subordinated notes due 2008.

The offer expires at 5 p.m. ET on July 5.

The company said it will pay $965.00 for each $1,000 principal amount of notes, plus accrued interest.

Enzon added that $260.223 million of notes is outstanding and said it may accept notes on a pro rata basis.

Goldman, Sachs & Co. is the dealer manager (800 828-3182 or call collect 212 357-7867). D.F. King & Co., Inc. is the information agent (800 290-6427 or call collect 212 269-5550).

Based in Bridgewater, N.J., Enzon is a biopharmaceutical company focused on cancer. It markets Abelcet and Oncaspar.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.